

Amendment
Docket No. 2804-US-DIV5
(formerly 2804-J)

Immunex Corporation

RECEIVED
CENTRAL FAX CENTER

DEC 14 2006

This listing of claims will replace all prior versions, and listings, of claims in the application:

What is claimed is:

1. (currently amended). An assay for detection of CD30 or CD30-L in a sample, comprising contacting the sample with a substantially homogeneous purified CD30-L polypeptide capable of binding CD30, wherein said CD30-L polypeptide is encoded by a DNA sequence that will hybridize to the nucleotide sequence presented in SEQ ID NO:19 18 or SEQ ID NO:23 22 under severely stringent conditions, and detecting binding of the sample thereto CD30 by CD30L.
2. (original). The assay of claim 1 which is a competitive binding assay.
3. (currently amended). The assay of claim 2, in which the CD30-L polypeptide is conjugated to a detectable moiety and used to detect binding of the sample CD30L to intact cells expressing cell surface CD30.
4. (original). The assay of claim 3, in the detectable moiety is selected from the group consisting of radionuclides, chromophores, an enzyme that can catalyze a colorometric reaction, an enzyme that can catalyze a fluorometric reaction, biotin, and avidin.
5. (currently amended). The assay of claim 2, in which the CD30-L polypeptide is conjugated to a detectable moiety and used to detect binding of the sample CD30L to a CD30 polypeptide bound to a solid phase.
6. (original). The assay of claim 5, in the detectable moiety is selected from the group consisting of radionuclides, chromophores, an enzyme that can catalyze a colorometric reaction, an enzyme that can catalyze a fluorometric reaction, biotin, and avidin.
7. (currently amended). An assay to detect cells expressing CD30 in a sample, comprising contacting the sample with a substantially homogeneous purified CD30-L polypeptide capable of binding CD30, wherein said CD30-L polypeptide is encoded by a DNA sequence that will hybridize to the nucleotide sequence presented in SEQ ID NO:19 18 or SEQ ID NO:23 22 under severely stringent conditions, and detecting binding of the CD30-L polypeptide bound to CD30 expressed by the cells.

Amendment
Docket No. 2804-US-DIV5
(formerly 2804-J)

Immunex Corporation

8. (original). The assay of claim 7, wherein the CD30-L polypeptide is conjugated to a detectable moiety selected from the group consisting of radionuclides, chromophores, an enzyme that can catalyze a colorometric reaction, an enzyme that can catalyze a fluorometric reaction, biotin, and avidin.

9. (currently amended). An assay to detect soluble CD30 in a sample, comprising contacting the sample with a substantially homogeneous purified CD30-L polypeptide capable of binding CD30, wherein said CD30-L polypeptide is encoded by a DNA sequence that will hybridize to the nucleotide sequence presented in SEQ ID NO:19 18 or SEQ ID NO:23 22 under severely stringent conditions, and detecting binding of the CD30-L polypeptide to the soluble CD30.

10. (original). The assay of claim 9, wherein the CD30-L polypeptide is conjugated to a detectable moiety selected from the group consisting of radionuclides, chromophores, an enzyme that can catalyze a colorometric reaction, an enzyme that can catalyze a fluorometric reaction, biotin, and avidin.

11. (currently amended). An assay for detection of CD30-L in a sample, comprising contacting the sample with an antibody immunoreactive with a CD30-L polypeptide encoded by a DNA sequence that will hybridize to the nucleotide sequence presented in SEQ ID NO:19 18 or SEQ ID NO:23 22 under severely stringent conditions, and detecting binding of the antibody to the CD30-L.

12. (original). The assay of claim 11 wherein the CD30-L is present on cells.

13. (original). The assay of claim 12, wherein the antibody is a monoclonal antibody.